drugset / Trial / NCT01861223
Afatinib Plus Nimotuzumb for NSCLC
NaSingle-groupOpen-labelTreatment
Summary
To find the optimal dose of afatinib and nimotuzumab in patients who acquired resistance to gefitinib or erlotinib.
Timeline
- Start
- 2013-05
- Primary completion
- 2015-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | — |
| Subject | Afatinib | Small molecule | 40 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 100 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |